HIV and hyperlipidemia: current recommendations and treatment

Area of Science:

• Cardiovascular Health and Infectious Diseases
• Metabolic Effects of Antiretroviral Therapy

Background:

• Cardiovascular disease (CVD) risk factors are increasingly recognized in individuals with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS).
• Highly Active Antiretroviral Therapy (HAART) regimens, particularly protease inhibitors, are associated with elevated triglyceride and cholesterol levels (dyslipidemia).
• Current hyperlipidemia treatments in HIV-positive individuals can be ineffective or dose-limited due to drug interactions.

Purpose of the Study:

• To evaluate the effectiveness of the National Cholesterol Education Program (NCEP) diet as a first-line management strategy for dyslipidemia in HIV-positive individuals.
• To address the need for well-controlled studies investigating dietary interventions in this population, given limitations in previous research (e.g., lack of randomization, control groups).
• To explore the metabolic impact of diet on lipid levels during HAART treatment, as underlying mechanisms remain incompletely understood.

Main Methods:

• The study proposes the implementation of rigorously controlled dietary intervention trials.
• Focus on randomization and inclusion of control groups to enhance study validity.
• Detailed description of the dietary counseling intervention will be incorporated.

Main Results:

• This section is to be populated upon study completion.
• Awaiting data from controlled trials to determine the efficacy of the NCEP diet.

Conclusions:

• Well-controlled dietary studies are essential to validate the NCEP diet for managing dyslipidemia in HIV/AIDS patients on HAART.
• Such studies will provide critical insights into the metabolic interplay between diet, HAART, and lipid profiles.
• Establishing effective dietary strategies is crucial for mitigating CVD risk in the growing population of individuals living with HIV/AIDS.